EEDVsMit

EEDVsMit (EGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone) is an investigational nanocell-based therapeutic developed by EnGeneIC Ltd. It is designed for the treatment of pediatric patients with recurrent or refractory solid tumors and central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG). The therapeutic consists of bacterially-derived nanocells, known as EnGeneIC Dream Vectors (EDVs), which package the chemotherapeutic agent mitoxantrone. These nanocells are targeted to tumor cells using bispecific antibodies that bind to both the epidermal growth factor receptor (EGFR) on the tumor cell surface and bacterial surface antigens on the EDV. Once bound, the EDVs are internalized via endocytosis, releasing mitoxantrone directly into the tumor cell to induce cell death by intercalating DNA and inhibiting topoisomerase II, thereby minimizing systemic toxicity.

Other names

EGFR-targeted EnGeneIC Dream Vector with mitoxantroneMitoxantrone packaged EDVEnGeneIC Delivery Vehicle with mitoxantrone